Compare TG Therapeutics Inc (TGTX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs ProShares Ultra Gold ETF — how do they compare? TG Therapeutics Inc trades at $55 (market cap $8.16B), while ProShares Ultra Gold ETF trades at $46.47 (market cap $716.59M). The key difference: TG Therapeutics Inc is far larger — about 11.4× ProShares Ultra Gold ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and ProShares Ultra Gold ETF for 23 Days on average.
| TGTX | UGL | |
|---|---|---|
Market Cap | $8.16B | $716.59M |
Volume | 1,735,121 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $85.62 |
52-Week Low | $26.94 | $42.79 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
UGL is trading at $46.45, up 4.55% today, but faces significant technical headwinds with a bearish overall signal. The stock shows neutral momentum oscillators but bearish moving averages, with key resistance at $46. Current financial ratios are unavailable, limiting fundamental assessment. Recent gold market volatility driven by Treasury yields and Fed policy expectations creates uncertainty for gold-related equities.
The outlook remains cautious given technical weakness and macroeconomic pressures on gold prices. Investment opportunity exists for contrarian investors if gold regains momentum, but risks include persistent rate hike expectations and dollar strength. Stock-specific fundamentals require verification through SEC filings for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
